share_log

Avenue Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

Avenue Therapeutics | SC 13G/A：超過5%持股股東披露文件(修正)

SEC announcement ·  01/02 13:00
牛牛AI助理已提取核心訊息
A regulatory filing with the United States Securities and Exchange Commission (SEC) on January 2, 2024, revealed that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz collectively reported a 4.99% stake in Avenue Therapeutics, Inc. The filing, an amendment to Schedule 13G, indicates shared voting and dispositive power over 661,056 shares of the company's common stock. Sabby Management, LLC, as the investment manager of Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz, in his capacity as manager of Sabby Management, LLC, do not directly own any shares but have an indirect interest in the same number of shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avenue Therapeutics, Inc. The principal executive offices of Avenue Therapeutics are located at 1140 Avenue of the Americas, Floor 9, New York, NY 10036.
A regulatory filing with the United States Securities and Exchange Commission (SEC) on January 2, 2024, revealed that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz collectively reported a 4.99% stake in Avenue Therapeutics, Inc. The filing, an amendment to Schedule 13G, indicates shared voting and dispositive power over 661,056 shares of the company's common stock. Sabby Management, LLC, as the investment manager of Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz, in his capacity as manager of Sabby Management, LLC, do not directly own any shares but have an indirect interest in the same number of shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avenue Therapeutics, Inc. The principal executive offices of Avenue Therapeutics are located at 1140 Avenue of the Americas, Floor 9, New York, NY 10036.
2024年1月2日向美國證券交易委員會（SEC）提交的監管文件顯示，Sabby波動率權證萬事達基金有限公司、Sabby Management, LLC和Hal Mintz共同報告了Avenue Therapeutics, Inc.4.99％的股份。該文件是附表13G的修正案，表明了對該公司661,056股普通股的共同投票權和處置權。作爲Sabby波動率權證萬事達基金有限公司的投資經理的Sabby Management, LLC和作爲Sabby Management, LLC經理的哈爾·明茨不直接擁有任何股份，但間接持有相同數量的股票的權益。該文件稱，收購這些股份不是爲了改變或影響Avenue Therapeutics, Inc.的控制權。Avenue Therapeutics的主要執行辦公室位於美洲大道1140號9樓，紐約10036。
2024年1月2日向美國證券交易委員會（SEC）提交的監管文件顯示，Sabby波動率權證萬事達基金有限公司、Sabby Management, LLC和Hal Mintz共同報告了Avenue Therapeutics, Inc.4.99％的股份。該文件是附表13G的修正案，表明了對該公司661,056股普通股的共同投票權和處置權。作爲Sabby波動率權證萬事達基金有限公司的投資經理的Sabby Management, LLC和作爲Sabby Management, LLC經理的哈爾·明茨不直接擁有任何股份，但間接持有相同數量的股票的權益。該文件稱，收購這些股份不是爲了改變或影響Avenue Therapeutics, Inc.的控制權。Avenue Therapeutics的主要執行辦公室位於美洲大道1140號9樓，紐約10036。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。